Does prophylactic antidepressant treatment boost interferon-alpha treatment completion in HCV?

doi:10.5501/wjv.v2.i4.139

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 4

This Article

(0)

(1938)

(3)

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Virology

ISSN

2220-3249

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article (XML)

Minireviews

World J Virol. Nov 12, 2013; 2(4): 139-145
Published online Nov 12, 2013. doi: 10.5501/wjv.v2.i4.139

Table 2 For studies reporting discontinuation data, number discontinuing interferon-alpha therapy, and reason for discontinuation, summed across studies

Reason for discontinuation	Prophylactic arm	Rescue arm
Lost to follow-up	21	19
Psychiatric side effects	8	18
Non-adherence	11	14
Did not complete therapy	3	3
Noncompliant or loss to follow-up	0	6
Other side effects	0	4

Full Size Table

Citation: Rowan PJ. Does prophylactic antidepressant treatment boost interferon-alpha treatment completion in HCV? World J Virol 2013; 2(4): 139-145
URL: https://www.wjgnet.com/2220-3249/full/v2/i4/139.htm
DOI: https://dx.doi.org/10.5501/wjv.v2.i4.139

Rowan PJ. Does prophylactic antidepressant treatment boost interferon-alpha treatment completion in HCV? World J Virol 2013; 2(4): 139-145 [PMID: 24255885 DOI: 10.5501/wjv.v2.i4.139]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.